Clinical trial
Abilify Therapy for Reducing Comorbid Substance Abuse
NCT00208169 · Creighton University, Other · Completed
Key facts
| NCT number | NCT00208169 |
|---|---|
| Title | Abilify Therapy for Reducing Comorbid Substance Abuse |
| Official title | Aripiprazole (Abilify) Therapy for Reducing Comorbid Substance Abuse |
| Lead sponsor | Creighton University, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder, Anxiety Disorders, Substance Abuse |
| Intervention type | Drug |
| Interventions | Aripiprazole |
| Enrollment | 30 |
| Start date | Mar 1, 2005 |
| Completion | Jun 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Aug 24, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: